Table 2.
Characteristics of the patients receiving T-cell infusions
| Patient | Sex/age at Tx, y | Tx | Immuno-suppression | Time from Tx to high viral load, mo | EBV-DNA load | Time from Tx to infusion, mo | Previous history of PTLD |
|---|---|---|---|---|---|---|---|
| 1 | F/3.1 | Liver | FK506 | 11 | 4 156 | 13 | No |
| 2 | F/1.1 | Liver | FK506 | 4 | 136 000 | 9.2 | No |
| 3 | M/1 | Liver | FK506 | 18 | 4 506 | 22 | Yes, adenoid: polymorphic, EBV+; removed 2 mo prior to CTL infusion |
| 4 | M/0.7 | Liver | FK506 | 4 | 16 204 | 18 | Yes, LN: PTLD of intermediated grade EBV+; removed 1 y prior to CTL infusion |
| 5 | F/0.6 | Liver | FK506 | 4 | 10 172 | 8 | No |
| 6 | M/1.6 | Liver | FK506 | 9 | 6 704 | 17 | Yes, diffuse lymphadenopathy: rituximab 5 mo prior to CTL infusion |
| 7 | F/3.3 | Liver | FK506 | 4 | 4 938 | 28 | Yes, gut: polymorphic EBV+, CD20+; rituximab 1 y prior to CTL infusion |
| 8 | F/2.1 | Liver | FK506 | 9 | 14 002 | 20 | No |
| 9 | M/3.5 | Heart | CsA | 60 | 2 500 | 68 | Yes, ocular PTLD; irradiation but loss of vision 1 y prior to CTL infusion |
| 10 | M/40 | Heart | CsA | 4 | 1 100 | 11 | No |
| 11 | F/1.1 | Heart | CsA | 142 | 1 500 | 155 | No |
| 12 | M/3.3 | Heart | CsA | 35 | 20 900 | 43 | Yes, ocular PTLD |
Tx indicates transplant; F, female; FK506, tacrolimus; M, male; LN, lymph node; and CsA, cyclosporin A.